

Full Length Research Paper

Helicobacter pylori Infection and Its Impact on Peptic Ulcer Disease Among Children in Albania

V. Velmishi^{1*}, G.Cekodhima², A. Cekodhima³, E.Dervishi¹, P Cullufi¹

¹Service of pediatric gastroenterology –Mother Teresa Hospital-Tirana, Albania

².Department of histopathology-Mother Teresa Hospital–Tirana, Albania

³.Gastroenterologist-“La vita” Endoscopic Clinic-Tirana ,Albania

Accepted 04 October, 2013

Aim: To evaluate the role of H pylori in peptic ulcer disease in albanian children according to clinical findings, histological data and eradication rate. **Methods and patients:** We have enrolled in this study all the patients who underwent to FGS for gastrointestinal symptoms during three years. We found 22 patients with peptic ulcer disease 20 of them with duodenal ulcer and 2 with gastric ulcer. For each patient we performed two biopsies (antrum and corpus) and one more antral biopsy for urease rapid test. After completing the data for 22 patients we have started eradication therapy for Hp positive group. Two months after therapy we have evaluated the eradication rate. For each patient we have included clinical, endoscopic and histological findings. **Results:** Of the 22 patients with peptic ulcer disease we found 17 patients infected by H pylori and 5 patients negative for H pylori. Range was from 8 years old to 14 years old (mean age was 11,3 years old). In this study with 22 patients there are 18 boys and 4 girls. Hp positive group had 14 boys and 3 girls while Hp negative group had 4 boys and 1 girl. Abdominal pain was equal with GI bleeding while the most frequent histological finding was chronic active gastritis. Of the 17 patients Hp positive 15 of them were negative for Hp two months after triple therapy. **Conclusion:** H. pylori play an important role in peptic ulcer disease in albanian children . His incidence is approximately 77 %. Male predomination was another interesting finding in our study. Eradication rate of H pylori was 88.2 %

Keywords: helicobacter pylori, peptic ulcer disease , fibrogastroduodenoscopy.

Background

Helicobacter pylori (Hp) is a gram-negative bacillus responsible for one of the most common infections found in humans worldwide (Blecker 1997). Warren and Marshall first cultured and identified the organism as *Campylobacter pylori* in 1982. By 1989, it was renamed and recognized to be associated closely with antral gastritis (gastric and

duodenal ulcers in adults and children). In recognition of this crucial discovery, they were awarded the Nobel Prize for medicine in 2005.

Peptic ulcer disease (PUD) affects up to 10 % of the general population (Bernersen et al., 1990; Wenger et al., 1985). Ulcer disease has been classified into primary and secondary ulcer. Today there are a lot of studies that confirm the link between primary ulcer and H. pylori infection. In Albania we have not an epidemiological study to evaluate the prevalence of H. pylori in general

*Corresponding Author's Email: tutimodh@yahoo.com




Figure 1. Flow chart of patients according to endoscopic findings and HP infection.
PUD:peptic ulcer disease; DU:duodenal ulcer;GU:gastric ulcer;HP:helicobacter pilory

population. Knowing that our country is a developing country we hypothesized that incidence of *H. pylori* in our population will be high. This is the first study in Albania that shows eradication rate of *H. pylori* in children with peptic ulcer disease.

According the most recent ESPGHAN and NASPGHAN guidelines is recommended eradication of the organism in children with peptic ulcer disease (Koletzko et al., 2011). Besides treatment studies on children are limited by the small number of infected children in each individual center (Francavilla et al., 2005; Odertda et al., 2007; Lionetti et al., 2010), we would like to give our opinion about the role of *H. pylori* in children with peptic ulcer disease.

PATIENTS AND METHODS

From January 2011 to January 2014 we enrolled all children who underwent to fibrogastroduodenoscopy for gastrointestinal symptoms. We have selected all children with peptic ulcer disease excluding medicaments ulcers, crohn ulcers etc. For each patient we performed standard techniques of endoscopy prescribing macroscopic findings (for example erythema, gastric nodularity, place of ulcer etc). We have taken two biopsies (antrum, corpus) and one more for urease rapid test (Pyloryset Urease–Orion diagnostica). Histological analyses are performed at our department of Histopathology at Mother Teresa Hospital. Biopsies were stained with hematoxylin –eosin. *H. pylori* presence, neutrophil infiltration, mononuclear infiltration, gastric atrophy or intestinal metaplasia were recorded according to Updated Sydney grading system. A patient was considered infected by *H. pylori* if biopsy result was positive. It was considered also infected by *H. pylori* a

child whose biopsy was negative but rapid urease test was strongly positive. We have considered “strongly positive” when rapid urease test is turned red in 15-30 minutes while interval of positivity for this test go to three hours. We divided patients in two groups Hp positive and Hp negative. Children Hp positive are treated with standard therapy for eradication of *H. pylori* according to the last recommendation of ESPGHAN and NASPGHAN. Our approved protocol of treatment was : PPI (1-2 mg/kg/d) q.d 4 weeks+ amoxicillin 50-70 mg/d b.i.d for one week + clarythromycine 15-20 mg/kg/d b.i.d for one week. One patient was treated with Metronidazole in place of amoxiciline because of previous penicillin side effects. Children Hp negative are treated only with PPI (1-2 mg/kg/d) for 4 weeks. We have evaluated eradication rate in Hp positive group two months after therapy performing again upper endoscopy with biopsy for histopatology and one more for rapid urease test.

RESULTS

We enrolled all children that underwent to upper digestive endoscopy for gastrointestinal symptoms. We found in total 22 patients with peptic ulcer disease. Interval of age was from 8 years old to 14 years old (mean age was 11,3 year). We had 20 patients with duodenal ulcer and two patients with gastric ulcer (see Figure 1). Of 22 patients diagnosed with peptic ulcer disease 18 of them were boys and 4 were girls (see Figure 2). After diagnostic test for *H. pylori* (biopsies and rapid urease test) we confirmed 17 patients Hp positive and 5 patients Hp negative (figure.1). Incidence of *H. pylori* in our group of patients was 77%. All Hp positive children were under standard triple therapy. As we




Figure 2. Sex difference in our group of children




Figure 3. Clinical findings at presentation, one month and 3 months after

mentioned before we have evaluated the eradication rate one month after triple therapy by upper digestive endoscopy taking again three biopsies. Two biopsies (corpus and antrum) for histopathology and one more in antrum for rapid urease test. Of 17 patients Hp positive only two patients were positive for H pylori. Eradication rate was 88.2%.

We evaluated clinical data at presentation, one month and three months later (see Figure 3). Of the 22 patients with peptic ulcer disease 11 of them presented abdominal pain as the first symptom (38%). 10 of them has presented symptoms of gastrointestinal bleeding (hematemesis or melena)(35%); 8 children presented vomits or nausea as the first symptom and one child(3%) has presented a syncopal episode as a result of severe anemia and hypotension (see Figure 4).

Histological data are evaluated according to Updated Sydney system. Of 17 patients HP positive the most frequent histopathological finding was Active chronic gastritis (11/17). 6 patients had chronic gastritis but low activity. Interesting was the fact that after eradication therapy histopathological view has changed dramatically. Histopathological images of 15 patients in Hp positive groupe didn't show neutrophil infiltration two months after therapy. Only two patients had the persistence of Hp infection with neutrophil and lymphoplasmacytic infiltration.

DISCUSSION

The discovery of H pylori by Marshall and Warren (Marshall and Warren 1984), has changed the




Figure 4. Chart that shows symptoms of our children at presentation

management for peptic ulcers. *H. pylori* infection is now considered to be the most important cause for primary peptic ulcers in both adults and children, and eradication of bacteria is effective in decreasing the ulcer relapse (Sherman et al., 2002; Malfertheiner et al., 1997).

However, contrary to most of previous reports that abdominal pain was the most common presentation (Drumm et al., 1988; Roma et al., 2001; Goggin et al., 1998), acute GI bleeding occurred as the primary presentation in 35% of our patients. An earlier study conducted in China, reviewing patients from 1975 to 1988, also found that acute GI bleeding to be the most common presentation (Chan et al., 1997). In our study we have quite the same number of children that presented gastrointestinal bleeding (10) compared with abdominal pain (11). Improvement of symptoms was very significant after therapy in both groups.

The sex difference between the *H. pylori* positive and the *H. pylori* negative group is also of great interest. Studies have shown a male predominance in peptic ulcer disease in children. Epidemiological studies do not suggest any sex predilection in *H. pylori* infection (Laine et al., 1998). We found that male predominance was only observed in the *H. pylori* positive group. Of 17 patients *Hp* positive we found 14 boys and 3 girls. On the other hand we had only five patients *Hp* negative (4 boys and 1 girl) but the small number of patients in this group could not be conclusive. In another study performed in our center we have included 94 patients with dyspeptic symptoms. Among them we found 56 *Hp* positives patients but the ratio between girls and boys was equal.

Histological findings in *H. pylori* –infected children have been extensively described elsewhere (Dixon et al., 1996; Guiraldes et al., 2002; Rubin 1997). For clinical management purposes, the most important information is whether *Helicobacter* is present. Variation in *H. pylori* density may have a bearing on disease associations and have epidemiological importance. (Davies et al., 1994; Stolte et al., 1995; Trespi et al., 1994). The most frequent finding in our group *Hp* positive was chronic active gastritis (see Figure 5). In general, gastritis is classified into acute and chronic. Chronic gastritis is divided into nonatrophic chronic gastritis usually caused by *Hp* infection, and atrophic gastritis composed of autoimmune and multifocal atrophic gastritis caused by *Hp* or dietary factors, as well as special forms of gastritis composed of reactive (chemical, reflux), radiation, lymphocytic, non infectious granulomatous, eosinophilic and other infectious gastritis (Capella et al., 1999; Rugge and Genta 2005; Makristathis et al., 2004; O’Keffe and Moran 2008). However the presence of *Hp* in a biopsy specimen does not mean that is the sole etiological agent. In some cases there are multiple etiological agents (Duck et al., 2004; Franceschi et al., 2002; Graham et al., 2004; Graham 2000). In our study histological change was very significant after eradication therapy. Histological amelioration in *Hp* positive patients goes parallel with eradication rate. We didn’t find any child with gastric atrophy or intestinal metaplasia. Those findings are very rare in pediatric age group and may arrive after years if children are not treated.

In our study *Hp* eradication was achieved in 88.2% of patients. Two patients were offered to second line therapy




Figure 5. The most frequent histopathology image in our Hp positive group: chronic active gastritis

(PPI 1-2 mg/kg/d q.d +amoxicilin 50-70 mg/kg/d b.i.d and metronidazole 20 mg/kg/d b.i.d) according to ESPGHAN/NASPGHAN recommendation, confirming the possibility of a high resistance to clarithromycin. In fact we did not performed susceptibility test because is not available in our center.

CONCLUSION

In Albanian children male sex is predominant in Peptic ulcer disease. Our study has shown that abdominal pain is quite equal with gastrointestinal bleeding as presentation signs of PUD in children. We had a high eradication rate in our group of Hp positive children. The most frequent histopathological finding in this group was chronic active gastritis. We have seen a normal histopathological view in the most part of our patients after eradication therapy.

Competing interest

The authors declare that they have no competing interests.

Authors` contributions

VV designed the study and wrote the manuscript; GC has contributed for histopathological analysis; AC has performed a part of upper endoscopy and designed the study; ED provided data collection; PC gave the final

approval of the version to be published. All authors read and approved the final manuscript.

REFERENCES

- Bedoya A, Garay J, Sanzon F, Bravo L, Bravo J, Correa H, Craver R, Fonham E, Du J, Bernersen B, Johnsen R, Straume B, Burhol PG, Jenssen TG, Stakkevold PA (1990). Towards a true prevalence of peptic ulcer: the Sorreisa gastrointestinal disorder study. *Gut* 1990;31:989-92.
- Blecker U (1997). Helicobacter pylori-associated gastroduodenal disease in childhood. *South Med J*. Jun 1997;90(6):570-6; quiz 577.
- Bourke B, Ceponis P, Chiba N (2005). Canadian Helicobacter Study Group Consensus Conference :update on the approach to Helicobacter pylori infection in children and adolescents –an evidence –based evaluation. *Can J Gastroenteol* 2005; 19:399-408.
- Capella R, Fiocca C, Cornaggia M (1999). Autoimmune gastritis . In :Graham D.Y, Genta R.M, Dixon M.F., EDS. Gastritis. Philadelphia;79-96.
- Chan KL, Tam PK, Saing H (1997). Long –term follow up of childhood duodenal ulcers.*J Pediatr Surg* 1997;32:1609-1611.
- Correa P (2003). Histopathology of gastritis in Helicobacter pylori-infected children from populations at high and low gastric cancer risk. *Human Pathology* 2003;34:206-213.
- Davies GR, Banatvaia N, Collins CE (1994). Relationship between infective load of Helicobacter pylori and reactive oxygen metabolite production in antral mucosa. *Scand J Gastroenterol* 1994;29:419-24
- Dixon MF, Genta RM, Yardley JH, Correa P (1996). Classification and grading of gastritis. The updated Sydney System. International workshop on the Histopathology of gastritis. Houston1994. *Am J Surg Pathol* 1996;20:1161-1181.
- Drumm B, Rhoads JM, Stringer DA (1988). Peptic ulcer disease in children: etiology, clinical findings and clinical course. *Pediatrics* 1988; 82:410-414

- Duck W.M, Sobel J, Pruckler JM (2004): Antimicrobial resistance incidence and risk factors among *Helicobacter pylori* –infected persons, United States. *Emerg Infect Dis* Jun ; 10(6):1088-1094.
- Francavilla R, Lionetti E, Castellaneta SP, Magista AM, Boscarelli G, Piscitelli D, Amoroso A, Di Leo A, Miniello VL, Francavilla A (2005). Improved efficacy of 10 – day sequential treatment for *Helicobacter pylori* eradication in children: a randomized trial .*Gastroenterology* 2005;129:1414-1419.
- Franceschi F, Genta R.M, Sepulveda A.R .(2002): Gastric mucosa: long – term outcome after cure of *Helicobacter pylori* infection . *J Gastroenterol*; 13:17-23.
- Goggin N, Rowland M, Imrie C (1998). Effect of *Helicobacter pylori* eradication on the natural history of duodenal ulcer disease. *Arch Dis Child* 1998; 79:502-505.
- Graham DY, Belson G, Abudayyeh S (2004): Twice daily (mid day and evening) quadruple therapy for H pylori infection in the United States. *Dig Liver Dis*: 36 (6) :384-387.
- Graham DY (2000). Therapy of *Helicobacter pylori*: current status and issues. *Gastroenterology*: 118:2-8.
- Guiraldes E, Peña A, Duarte I, Triviño X, Schultz M, Larraín F, Espinoza N, Harris P (2002). Nature and extent of gastric lesions in symptomatic Chilean children with *Helicobacter- pylori* associated gastritis. *Acta Pediatrica* 2002;91:39-44.
- Harris PR, Wright SW, Serrano C, Riera F, Duarte I, Torres J, Peña A, Rollán A, Viviani P, Guiraldes E, Schmitz JM, Lorenz RG, Novak L, Smythies LE, Smith PD (2003). *Helicobacter pylori* in children is associated with a regulatory T-cell response. *Gastroenterol* 2008;134:491-9.
- Koletzko S, Jones NL, Goodman KJ (2011). Evidence-based guidelines from ESPGHAN and NASPGHAN for *Helicobacter pylori* infection in children. *J Pediatr Gastroenterol Nutr*. Aug 2011;53 (2):230-43.
- Laine L, Hopkins RJ, Giarardi L S (1998). Has the impact of *Helicobacter pylori* therapy on ulcer recurrence in the United States been overstated? A meta –analysis of rigorously designed trials. *Am J Gastroenterol* 1998 ;93:1409-1415
- Lionetti E, Indrio F, Pavone L, Borrelli G, Cavallo L, Francavilla R (2010). Role of probiotics in pediatric patients with *Helicobacter pylori* infection: a comprehensive review of the literature. *Helicobacter* 2010;15:79-87.
- Makristathis A, Hirschl AM, Lehours Ph, Megraud F (2004). Diagnosis of *Helicobacter pylori* infection. *Helicobacter* ;9(1): 7-14.
- Malfertheiner P, Megraud F, O'Morain C (1997). Current European concepts in the management of *Helicobacter pylori* infection – the Maastricht Consensus Report. The European *Helicobacter Pylori* Study Group (EHPSG). *Eur J Gastroenterol Hepatol* 1997; 9:1-2.
- Marshall BJ, Warren JR (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; 1:1311
- NIH Consensus Development Panel., *Helicobacter pylori* in peptic ulcer disease. *JAMA*; 272: 65-9.
- O'Keffe J, Moran AP (2008). Conventional , Regulatory , and Unconventional T cells in the Immunologic Response to *Helicobacter pylori*, *Helicobacter*; 13 :1-19
- Oderda G, Shcherbakov P, Bontem P, Urruzuno P, Romano C, Gottrand F, Gomez MJ, Ravelli A, Gandullia P, Gandullia P, Roma E (2007). European Pediatric Task Force on *Helicobacter pylori* , et Al : Results from the pediatric European register for treatment of *Helicobacter pylori* (PERTH). *Helicobacter pylori* 2007;12:150-156
- Roma E, Kafritsa Y, Panayiotou J (2001). Is peptic ulcer a common cause of upper gastrointestinal symptoms ? *Eur J Pediatr* 2001; 160: 497-500.
- Rubin C (1997). Are there three types of *Helicobacter pylori* gastritis?. *Gastroenterol* 1997;112: 2108-10.
- Rugge M, Genta RM (2005). Staging and grading of chronic gastritis. *Hum Pathol*; 36(3):228-223.
- Sherman P, Czinn S, Drumm B (2002). *Helicobacter pylori* in children and adolescents: working group report of the First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr* 2002; 35:128-133.
- Stolte M, Stadelmann O, Bethke B, Burkard G (1995). Relationship between the degree of *Helicobacter pylori* colonisation and the degree of gastritis, surface epithelial degeneration and mucus secretion. *Z. Gastroenterol* 1995; 89-93
- Trespi E, Broglia F, Villans L, Luinetti O , Fiocca R, Solcia E (1994). Distinct profiles of gastritis in dyspepsia subgroups . Their different clinical responses to gastritis healing after *Helicobacter pylori* eradication . *Scand J Gastroenterol* 1994;29:884-8
- Wenger J, Hebel E, Gutierrez C, Guiraldes E (1985). Úlcera Péptica en Pediatría: Experiencia de 10 años. *Rev Chil Pediatr* 1985; 56:435-440.